Who are Eflornithine Topical's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eflornithine hydrochloride cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eflornithine-topical.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Eflornithine Topical — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eflornithine Topical (Eflornithine Topical) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ornithine decarboxylase inhibitor. Area: Dermatology.

marketed Ornithine decarboxylase inhibitor Ornithine decarboxylase (ODC) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Eflornithine Topical (Eflornithine Topical) — Khyber Teaching Hospital. Eflornithine inhibits ornithine decarboxylase, reducing polyamine synthesis and slowing hair growth.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eflornithine Topical TARGET	Eflornithine Topical	Khyber Teaching Hospital	marketed	Ornithine decarboxylase inhibitor	Ornithine decarboxylase (ODC)
Eflornithine hydrochloride cream	Eflornithine hydrochloride cream	National Skin Centre	phase 3	Ornithine decarboxylase inhibitor	Ornithine decarboxylase (ODC)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ornithine decarboxylase inhibitor class)

Khyber Teaching Hospital · 1 drug in this class
National Skin Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eflornithine Topical — Competitive Intelligence Brief. https://druglandscape.com/ci/eflornithine-topical. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing